Inflazome   Report issue

For profit Phase 1
Founded: Dublin Ireland (2016)
Status: Acquired by Roche (2020)

Organization Overview

First Clinical Trial
2019
NCT04015076
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Inflazome UK Ltd

Active Ingredients

Drugs in Phase 1 Trials (2)

inzomelid (2 trials)

izd334 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Cryopyrin-Associated Periodic Syndromes (Phase 1)

Parkinson Disease (Phase 1)

Syndrome (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 3
  • # of Trial APIs: 2